1. Home
  2. AMGN vs GE Comparison

AMGN vs GE Comparison

Compare AMGN & GE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Amgen Inc.

AMGN

Amgen Inc.

N/A

Current Price

$437.81

Market Cap

251.6B

Sector

Health Care

ML Signal

N/A

Logo General Electric Company

GE

General Electric Company

N/A

Current Price

$310.32

Market Cap

296.4B

Sector

Technology

ML Signal

N/A

Company Overview

Basic Information
Metric
AMGN
GE
Founded
1980
1892
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Consumer Electronics/Appliances
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
251.6B
296.4B
IPO Year
2002
2008

Fundamental Metrics

Financial Performance
Metric
AMGN
GE
Price
$437.81
$310.32
Analyst Decision
Hold
Buy
Analyst Count
34
23
Target Price
★ $435.77
$378.43
AVG Volume (30 Days)
2.1M
★ 4.4M
Earning Date
11-03-2026
10-20-2026
Dividend Yield
★ 2.30%
0.59%
EPS Growth
★ 88.23
35.89
EPS
★ 14.79
6.27
Revenue
$25,424,000,000.00
★ $45,855,000,000.00
Revenue This Year
$7.45
$10.96
Revenue Next Year
$4.54
$11.69
P/E Ratio
★ $29.67
$50.85
Revenue Growth
8.83
★ 18.48
52 Week Low
$312.39
$268.91
52 Week High
$483.99
$388.84

Technical Indicators

Market Signals
Indicator
AMGN
GE
Relative Strength Index (RSI) 41.75 43.82
Support Level $338.02 $304.80
Resistance Level $446.42 $316.77
Average True Range (ATR) 11.75 10.43
MACD -4.96 -1.19
Stochastic Oscillator 4.16 2.65

Price Performance

Historical Comparison
AMGN
GE

About AMGN Amgen Inc.

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

About GE General Electric Company

GE Aerospace is the global leader in designing, manufacturing, and servicing commercial aircraft turbine engines, along with partner Safran in their CFM joint venture. With its massive global installed base of nearly 80,000 commercial and military engines, GE Aerospace earns most of its profits on recurring service revenue of that equipment, which operates for decades. GE Aerospace is the remaining core business of the company formed in 1892 with historical ties to American inventor Thomas Edison; General Electric became a storied conglomerate, with peak revenue of $130 billion in 2000, until it spun off its appliance, finance, healthcare, and wind and power businesses between 2016 and 2024.

Share on Social Networks: